IMMUNITYBIO, INC. Lease, Cost
IMMUNITYBIO, INC. (IBRX) reported Lease, Cost of $4.86 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-05-07
- IMMUNITYBIO, INC. lease, cost for the quarter ending 2026-03-31 was $4.86M, a 5.49% increase year-over-year.
- IMMUNITYBIO, INC. lease, cost for the quarter ending 2025-12-31 was $4.69M, a 3.10% decline year-over-year.
- IMMUNITYBIO, INC. lease, cost for the quarter ending 2025-09-30 was $4.51M, a 2.21% decline year-over-year.
- IMMUNITYBIO, INC. lease, cost for the quarter ending 2025-06-30 was $4.83M, a 5.11% increase year-over-year.
- IMMUNITYBIO, INC. lease, cost for fiscal 2025 was $18.64M, a 0.42% increase from fiscal 2024.
- IMMUNITYBIO, INC. lease, cost for fiscal 2024 was $18.56M, a 1.38% decline from fiscal 2023.
- IMMUNITYBIO, INC. lease, cost for fiscal 2023 was $18.82M, a 3.90% increase from fiscal 2022.
- IMMUNITYBIO, INC. lease, cost for fiscal 2022 was $18.11M, a 67.11% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $4.86M 10-Q · filed 2026-05-07 | $9.55M derived: sum of 2 quarters · filed 2026-05-07 | $14.06M derived: sum of 3 quarters · filed 2026-05-07 | $18.89M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $9.20M derived: sum of 2 quarters · filed 2026-02-23 | $14.03M derived: sum of 3 quarters · filed 2026-02-23 | $18.64M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $4.51M 10-Q · filed 2025-11-05 | $9.34M derived: sum of 2 quarters · filed 2025-11-05 | $13.95M 10-Q · filed 2025-11-05 | $18.79M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-06-30 | $4.83M 10-Q · filed 2025-08-05 | $9.44M 10-Q · filed 2025-08-05 | $14.28M derived: sum of 3 quarters · filed 2026-05-07 | $18.89M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2025-03-31 | $4.61M 10-Q · filed 2026-05-07 | $9.45M derived: sum of 2 quarters · filed 2026-05-07 | $14.06M derived: sum of 3 quarters · filed 2026-05-07 | $18.66M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $9.45M derived: sum of 2 quarters · filed 2026-02-23 | $14.05M derived: sum of 3 quarters · filed 2026-02-23 | $18.56M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $4.61M 10-Q · filed 2025-11-05 | $9.21M derived: sum of 2 quarters · filed 2025-11-05 | $13.72M 10-Q · filed 2025-11-05 | $17.91M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-06-30 | $4.59M 10-Q · filed 2025-08-05 | $9.11M 10-Q · filed 2025-08-05 | $13.30M derived: sum of 3 quarters · filed 2026-02-23 | $18.06M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2024-03-31 | $4.51M 10-Q · filed 2025-05-12 | $8.71M derived: sum of 2 quarters · filed 2026-02-23 | $13.47M derived: sum of 3 quarters · filed 2026-02-23 | $18.37M derived: sum of 4 quarters · filed 2026-02-23 | |
| 2023-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.96M derived: sum of 2 quarters · filed 2026-02-23 | $13.86M derived: sum of 3 quarters · filed 2026-02-23 | $18.82M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $4.76M 10-Q · filed 2024-11-12 | $9.66M derived: sum of 2 quarters · filed 2024-11-12 | $14.63M 10-Q · filed 2024-11-12 | $19.58M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $4.90M 10-Q · filed 2024-08-12 | $9.86M 10-Q · filed 2024-08-12 | $14.82M derived: sum of 3 quarters · filed 2025-03-03 | $20.61M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $4.96M 10-Q · filed 2024-05-09 | $9.92M derived: sum of 2 quarters · filed 2025-03-03 | $15.71M derived: sum of 3 quarters · filed 2025-03-03 | $19.59M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $10.75M derived: sum of 2 quarters · filed 2025-03-03 | $14.62M derived: sum of 3 quarters · filed 2025-03-03 | $18.11M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $5.79M 10-Q · filed 2023-11-09 | $9.67M derived: sum of 2 quarters · filed 2023-11-09 | $13.16M 10-Q · filed 2023-11-09 | $16.55M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-06-30 | $3.88M 10-Q · filed 2023-08-08 | $7.37M 10-Q · filed 2023-08-08 | $10.76M derived: sum of 3 quarters · filed 2024-03-19 | $13.16M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2022-03-31 | $3.49M 10-Q · filed 2023-05-11 | $6.88M derived: sum of 2 quarters · filed 2024-03-19 | $9.28M derived: sum of 3 quarters · filed 2024-03-19 | $11.52M derived: sum of 4 quarters · filed 2024-03-19 | |
| 2021-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $5.79M derived: sum of 2 quarters · filed 2024-03-19 | $8.03M derived: sum of 3 quarters · filed 2024-03-19 | $10.84M 10-K · filed 2024-03-19 | |
| 2021-09-30 | $2.40M 10-Q · filed 2022-11-09 | $4.64M derived: sum of 2 quarters · filed 2022-11-09 | $7.45M 10-Q · filed 2022-11-09 | $9.93M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $2.23M 10-Q · filed 2022-08-08 | $5.05M 10-Q · filed 2022-08-08 | $7.53M derived: sum of 3 quarters · filed 2023-03-01 | $9.30M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $2.81M 10-Q · filed 2022-05-10 | $5.29M derived: sum of 2 quarters · filed 2023-03-01 | $7.07M derived: sum of 3 quarters · filed 2023-03-01 | $9.41M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $4.25M derived: sum of 2 quarters · filed 2023-03-01 | $6.60M derived: sum of 3 quarters · filed 2023-03-01 | $9.23M 10-K · filed 2023-03-01 | $6.22M 10-K · filed 2021-03-04 |
| 2020-09-30 | $1.77M 10-Q · filed 2021-11-12 | $4.12M derived: sum of 2 quarters · filed 2021-11-12 | $6.75M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $2.35M 10-Q · filed 2021-08-12 | $4.98M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $2.63M 10-Q · filed 2021-05-14 | ||||
| 2019-12-31 | $8.56M 10-K · filed 2022-03-01 | $5.11M 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |